Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Beyondspring Pharmaceuticals Inc. currently has 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 4 actions are spread across 4 distinct art units and 4 distinct examiners. This one-to-one ratio between actions, examiners, and art units indicates a highly decentralized prosecution profile for the company's current pending matters. This distribution across 4 distinct art units suggests that the company's current patent applications cover a broad range of technical topics within the biotechnology and pharmaceuticals field.
BRUCK KIFLE is listed as the busiest examiner, handling 1 pending office action. Because the 4 pending office actions are distributed among 4 distinct examiners, no single examiner holds a majority of the workload. Practitioners must manage 4 distinct examiners across 4 distinct art units, requiring a versatile approach to prosecution. The lack of concentration in any single art unit or under any single examiner means that each of the 4 pending office actions will likely follow a unique path toward resolution.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIFLE, BRUCK | 1 | 79.2% | +15.9% |
| PECKHAM, RICHARD GRANT | 1 | 68.1% | +35.1% |
| GODDARD, LAURA B | 1 | 50.9% | +13.5% |
| HUANG, GIGI GEORGIANA | 1 | 31.8% | +30.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17923189 | TRIPLE COMBINATION THERAPY FOR ENHANCING CANCER CELL KILLING IN CANCERS WITH LOW IMMUNOGENICITY | GODDARD, LAURA B | 9d |
| 18554595 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING TUMORS | PECKHAM, RICHARD GRANT | 26d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17923189 | TRIPLE COMBINATION THERAPY FOR ENHANCING CANCER CELL KILLING IN CANCERS WITH LOW IMMUNOGENICITY | GODDARD, LAURA B | 9d |
| 18554595 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING TUMORS | PECKHAM, RICHARD GRANT | 26d |
| 18671711 | PLINABULIN COMPOSITIONS | KIFLE, BRUCK | 34d |
| 16966156 | COMPOSITION AND METHOD FOR REDUCING CHEMOTHERAPY-INDUCED NEUTROPENIA VIA THE ADMINISTRATION OF PLINABULIN AND A G-CSF AGENT | HUANG, GIGI GEORGIANA | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1627 | 1 |
| 1642 | 1 |
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18671711 | PLINABULIN COMPOSITIONS | KIFLE, BRUCK | 1624 | §112Other | Non-Final OA | 34d | Pending | May 22, 2024 |
| 18554595 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING TUMORS | PECKHAM, RICHARD GRANT | 1627 | §103§112Other | Non-Final OA | 26d | Pending | Oct 09, 2023 |
| 17923189 | TRIPLE COMBINATION THERAPY FOR ENHANCING CANCER CELL KILLING IN CANCERS WITH LOW IMMUNOGENICITY | GODDARD, LAURA B | 1642 | §102§103Other | Non-Final OA | 9d | Pending | Nov 03, 2022 |
| 16966156 | COMPOSITION AND METHOD FOR REDUCING CHEMOTHERAPY-INDUCED NEUTROPENIA VIA THE ADMINISTRATION OF PLINABULIN AND A G-CSF AGENT | HUANG, GIGI GEORGIANA | 1613 | §103§112DPOther | Non-Final OA | — | Pending | Jul 30, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial